Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
Journal of Clinical Oncology (2017)
  • John Francis Seymour, Peter MacCallum Cancer Centre
  • Matthew Steven Davids, Harvard University
  • John M. Pagel, Cancer Institute
  • Brad S. Kahl, University of Wisconsin-Madison
  • William G. Wierda, Cardiff University
  • Thomas P. Miller, University of Arizona
  • John F. Gerecitano, Memorial Sloan Kettering Cancer Center
  • Thomas J. Kipps, University of California, San Diego
  • Mary Ann Anderson, Royal Melbourne Hospital
  • David C.S. Huang, Walter and Eliza Hall Institute of Medical Research
  • David E. Darden
  • Lori A. Gressick
  • Cathy E. Nolan
  • Jianning Yang
  • Todd A. Busman, Walter and Eliza Hall Institute of Medical Research
  • Alison M. Graham
  • Elisa Cerri, University of Chicago
  • Sari H. Enschede, Rush University Medical Center
  • Rod A. Humerickhouse, Roswell Park Cancer Institute
  • Andrew Warwick Roberts, Royal Melbourne Hospital
Link
Disciplines
Publication Date
January 30, 2017
Citation Information
John Francis Seymour, Matthew Steven Davids, John M. Pagel, Brad S. Kahl, et al.. "Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)." Journal of Clinical Oncology (2017)
Available at: http://works.bepress.com/john-pagel/25/